2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications


  • The Cytometry Part B: Clinical Cytometry supplement (72B, Supplement 1, 2007) titled ‘2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia’ is sponsored by the Clinical Cytometry Society and the Clinical Cytometry Foundation. The Conference was supported by AmeriPath, ARUP, Beckman Coulter, BD Biosciences, CLARIENT, Clinical Cytometry Foundation, Clinical Cytometry Society, GENOPTIX, Genzyme, Laboratory Corporation of America, Trillium Diagnostics, National Cancer Institute, and Wallace H. Coulter Foundation. The contributing authors to this article have declared the following conflicts of interest: Jeannine Holden has received research funding from BD Biosciences and has worked as a consultant for Dianon. Michael J. Borowitz has received support from BD Biosciences for some of his research work. This work is not the subject of the manuscript under consideration. Russell L. Maiese is an employee of and holds stock in AmeriPath. Brent Lee Wood has acted as a paid consultant and/or accepted speaker's fees from BD Biosciences and Beckman Coulter in the past, but has received no funding relevant to the current work. Denise A. Wells, M.D., is the Medical Directory for Hematologics, Inc., a laboratory that performs flow cytometric analysis. The remaining authors have declared no conflicts of interest.


The clinical indications for diagnostic flow cytometry studies are an evolving consensus, as the knowledge of antigenic definition of hematolymphoid malignancies and the prognostic significance of antigen expression evolves. Additionally the standard of care is not routinely communicated to practicing clinicians and diagnostic services, especially as may relate to new technologies. Accordingly there is often uncertainty on the part of clinicians, payers of medical services, diagnostic physicians and scientists as to the appropriate use of diagnostic flow cytometry. In an attempt to communicate contemporary diagnostic utility of immunophenotypic flow cytometry in the diagnosis and follow-up of patients with hematolymphoid malignancies, the Clinical Cytometry Society organized a two day meeting of international experts in this area to reach a consensus as to this diagnostic tool. This report summarizes the appropriate use of diagnostic flow cytometry as determined by unanimous approval of these experienced practitioners. © 2007 Clinical Cytometry Society